FDA's enforcement of promotional material has continued to dwindle in recent years, but while the volume has dropped, the pattern in many ways remains the same: The Office of Prescription Drug Promotion (OPDP) has just cited a display from the American Society for Clinical Oncology (ASCO) Annual Meeting – only the office's third letter of the year.
This time, Celator Pharmaceuticals Inc. was deemed the culprit, with the agency saying a placard for the...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?